Update: Potential confirmed but checkpoint data needed
The therapeutic potential of Transgene’s TG4010 in non-squamous non-small cell lung cancer (NSCLC) was supported by the more mature overall survival (OS) Phase IIb data. However, we expect that additional data from combination studies with checkpoint inhibitors will be required for TG4010 to be out-licensed; these trials should start in H215. Transgene is also planning to initiate a Phase I study with TG1050 for chronic HBV infection. We maintain our valuation at €464m.Transgene is a biopharmaceutical company that designs and develops immunotherapy and virotherapy products for the treatment of cancers and infectious diseases. Co. is developing three anti-cancer products that are in clinical trials: (cancer of the lungs, liver and oropharynx); two anti-infectious immunotherapy products also in clinical trials: (hepatitis B and C). Co. also has products in the pre-clinical development stage. Co. operates in a single business segment, the research and development of therapeutic vaccines and immunotherapy products. Co. does not have any products on the market. Substantially all of its operations are conducted in France.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.